Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

Table 5

Relationship between positive rate of the STIP1 autoantibodies and clinical data in ESCC patients from the validation cohort.

	N	Positive (%, 95% CI)	P
Age
≥58	32	13 (40.6, 24.2–59.2)	0.916
<58	28	11 (39.3, 22.2–59.3)
Gender
Male	38	14 (36.8, 22.3–54.0)	0.512
Female	22	10 (45.5, 25.1–67.3)
Smoke
Yes	36	13 (36.1, 21.3–53.8)	0.451
No	24	11 (45.8, 26.2–66.8)
Site of tumor
Upper thorax	10	3 (30.0, 8.1–64.6)	0.724
Middle thorax + low thorax	50	21 (42.0, 28.5–56.7)
Size of tumor
<5 cm	24	9 (37.5, 19.6–59.2)	0.747
≥5 cm	36	15 (41.7, 26.0–59.1)
Depth of tumor invasion
T1 + T2	21	9 (42.9, 22.6–65.6)	0.800
T3 + T4	38	15 (39.5, 24.5–56.5)
Regional lymph nodes
N0	31	12 (38.7, 22.4–57.7)	0.833
N1 + N2 + N3	29	12 (41.4, 24.1–60.9)
Histological grade
G1	17	6 (35.3, 15.3–61.4)	0.659
G2	36	16 (44.4, 28.3–61.7)
G3	7	2 (28.6, 5.1–69.7)
TNM stage
Early stage (0 + I + IIA)	13	5 (38.5, 15.1–67.7)	0.898
Advanced stage (IIB + III + IV)	47	19 (40.4, 26.7–55.7)

ESCC: esophageal squamous cell carcinoma; CI: exact confidence interval. Statistical significance was determined using the chi-square test.